Tag: <span>viral gene vectors</span>

From the Editor-in-Chief: Many of the Toughest Biologicals are Becoming Easier to Produce

There are so many exciting things happening in the biotech industry. As we have all seen, antibody products are being approved for more and more cancer applications, in addition to those for auto-immune diseases, which used to dominate how they were being used. And of course, these applications are in addition to the many which use antibodies conjugated to chemotherapeutic drugs and imaging agents—where the antibody acts as a targeting mechanism. Then there are the hundreds of monoclonal and polyclonal antibody applications that have dominated diagnostic testing for decades…

Read MoreFrom the Editor-in-Chief: Many of the Toughest Biologicals are Becoming Easier to Produce

Biologics Production

aav adeno-associated virus air handling antibody conjugates biologics bioproduction cryopreservation diagnostic testing ind investigational new drug lentiviral vector systems monoclonal antibodies polyclonal antibodies regenerative tissues subunit vaccines transient transfection viral gene vectors

From the Editor-in-Chief: Production Technology for Lentiviral Vectors

I’ve had some very interesting technical issues cross my desk in the last month, and one involves the “state-of-the-art” production technology for lentiviral vectors. And while you’d think this process should be quite advanced since the industry has been manufacturing viral gene vectors for over 20 years, it appears that we’ve fallen back on old technology and we’re dealing with processing issues we would typically avoid…

Read MoreFrom the Editor-in-Chief: Production Technology for Lentiviral Vectors

Biologics Production

attachment-dependent production biologics bioproduction fbs fetal bovine serum hek 293 cells hek 293T human embryonic kidney lentiviral vector systems packed bed bioreactor stable cell lines sv40 t antigen viral gene vectors

From the Editor-in-Chief: Major Successes in the Industry and Primary Challenges That Follow

As biologics continue to advance at a dizzying pace, I want to take this opportunity to outline what I see as the major successes, as well as the primary challenges facing the industry. First, the science of antibody production appears to be quite settled. Significant value can be gained by finding ways to limit production batches to volumes that can be accommodated by single-use bioreactor systems…

Read MoreFrom the Editor-in-Chief: Major Successes in the Industry and Primary Challenges That Follow

Biologics Production

biologics bioproduction cellular therapies continuous downstream processing cryopreservation challenges downstream purification monoclonal antibodies personalized medicine real-time data scale-out scale-up single-use equipment viral gene vectors

From the Editor-in-Chief: The Biotech Industry Continues to Improve

It appears that the state of the biotech industry continues to improve. We now have a licensed cellular therapy that Dendreon developed, and which has now been sold to another firm that thinks it can make and administer this prostate cancer vaccine more efficiently, plus provide a more effective product. There is also a viral gene vector that has been licensed in Europe, and an application for US licensing has been submitted. Then there is the licensed influenza vaccine that is made with baculovirus technology, plus a second baculovirus-derived flu vaccine that is near licensure. The two companies with these flu vaccines are now charging ahead with their baculovirus expertise to produce Ebola vaccines…

Read MoreFrom the Editor-in-Chief: The Biotech Industry Continues to Improve

Biologics Production

autologous cellular vaccine baculovirus expression biologics bioproduction biosimilars cancer vaccines cellular therapies cryoprotectant ebolavirus vaccine immunogenicity m&a mergers and acquisitions viral gene vectors